Oncolytics Biotech Files 6-K Report

Ticker: ONCY · Form: 6-K · Filed: Jul 16, 2025 · CIK: 1129928

Sentiment: neutral

Topics: reporting, foreign-private-issuer, sec-filing

TL;DR

Oncolytics Biotech filed a routine 6-K, no major news.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on July 16, 2025, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is a pharmaceutical preparations company and is subject to the 1934 Securities Exchange Act. This filing does not appear to contain specific financial or operational updates beyond its status as a periodic report.

Why It Matters

This filing indicates Oncolytics Biotech Inc. is meeting its reporting obligations as a foreign private issuer, which is standard for publicly traded companies operating internationally.

Risk Assessment

Risk Level: low — This is a standard periodic filing by a foreign private issuer and does not contain new material information that would inherently increase risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes public in its home country, files with a stock exchange, or distributes to its security holders.

When was this Form 6-K filed?

This Form 6-K was filed on July 16, 2025.

Where is Oncolytics Biotech Inc. headquartered?

Oncolytics Biotech Inc. is headquartered in Calgary, Alberta, Canada.

What is the company's Standard Industrial Classification (SIC) code?

The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Does this filing indicate a new annual report submission?

The filing indicates whether the registrant files annual reports under Form 20-F or Form 40-F, but this specific 6-K filing itself is not an annual report.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 16, 2025 regarding ONCOLYTICS BIOTECH INC (ONCY).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing